Oscar Matzinger1, David Viertl2, Pelagia Tsoutsou3, Linda Kadi4, Stefania Rigotti4, Claudio Zanna4, Norbert Wiedemann4, Marie-Catherine Vozenin5, Grégoire Vuagniaux4, Jean Bourhis2. 1. Laboratory of Radiation Oncology Department, University Hospital of Lausanne (CHUV), Switzerland; Radiation Oncology Department, Hôpital Riviera-Chablais, Vevey, Switzerland. 2. Laboratory of Radiation Oncology Department, University Hospital of Lausanne (CHUV), Switzerland. 3. Laboratory of Radiation Oncology Department, University Hospital of Lausanne (CHUV), Switzerland; Radiation Oncology Department Hôpital du Valais, Sion, Switzerland. 4. Debiopharm International SA, Lausanne, Switzerland. 5. Laboratory of Radiation Oncology Department, University Hospital of Lausanne (CHUV), Switzerland. Electronic address: marie-catherine.vozenin@chuv.ch.
Abstract
BACKGROUND AND PURPOSE: Second mitochondria-derived activator of caspase (SMAC)-mimetics are a new class of targeted drugs that specifically induce apoptotic cancer cell death and block pro-survival signaling by antagonizing selected members of the inhibitor of apoptosis protein (IAP) family. MATERIAL AND METHODS: The present study was designed to investigate the radiosensitizing effect and optimal sequence of administration of the novel SMAC-mimetic Debio 1143 in vitro and in vivo. Apoptosis, alteration of DNA damage repair (DDR), and tumor necrosis factor-alpha (TNF-α) signaling were examined. RESULTS: In vitro, Debio 1143 displayed anti-proliferative activity and enhanced intrinsic radiation sensitivity in 5/6 head and neck squamous cell carcinoma (HNSCC) cell lines in a synergistic manner. In vivo, Debio 1143 dose-dependently radio-sensitized FaDu and SQ20B xenografts, resulting in complete tumor regression in 8/10 FaDu-xenografted mice at the high dose level. At the molecular level, Debio 1143 combined with radiotherapy (RT) induced enhancement of caspase-3 activity, increase in Annexin V-positive cells and karyopyknosis, and increase in TNF-α mRNA levels. Finally, in a neutralization experiment using a TNF-α-blocking antibody and a caspase inhibitor, it was shown that the radiosensitizing effect of Debio 1143 is mediated by caspases and TNF-α. CONCLUSIONS: These results demonstrate that the novel SMAC-mimetic Debio 1143 is a radiosensitizing agent that is worthy of further investigation in clinical trials in combination with radiotherapy.
BACKGROUND AND PURPOSE:Second mitochondria-derived activator of caspase (SMAC)-mimetics are a new class of targeted drugs that specifically induce apoptotic cancer cell death and block pro-survival signaling by antagonizing selected members of the inhibitor of apoptosis protein (IAP) family. MATERIAL AND METHODS: The present study was designed to investigate the radiosensitizing effect and optimal sequence of administration of the novel SMAC-mimetic Debio 1143 in vitro and in vivo. Apoptosis, alteration of DNA damage repair (DDR), and tumor necrosis factor-alpha (TNF-α) signaling were examined. RESULTS: In vitro, Debio 1143 displayed anti-proliferative activity and enhanced intrinsic radiation sensitivity in 5/6 head and neck squamous cell carcinoma (HNSCC) cell lines in a synergistic manner. In vivo, Debio 1143 dose-dependently radio-sensitized FaDu and SQ20B xenografts, resulting in complete tumor regression in 8/10 FaDu-xenografted mice at the high dose level. At the molecular level, Debio 1143 combined with radiotherapy (RT) induced enhancement of caspase-3 activity, increase in Annexin V-positive cells and karyopyknosis, and increase in TNF-α mRNA levels. Finally, in a neutralization experiment using a TNF-α-blocking antibody and a caspase inhibitor, it was shown that the radiosensitizing effect of Debio 1143 is mediated by caspases and TNF-α. CONCLUSIONS: These results demonstrate that the novel SMAC-mimetic Debio 1143 is a radiosensitizing agent that is worthy of further investigation in clinical trials in combination with radiotherapy.
Authors: Roy Xiao; Clint T Allen; Linda Tran; Priya Patel; So-Jin Park; Zhong Chen; Carter Van Waes; Nicole C Schmitt Journal: Oncoimmunology Date: 2018-08-01 Impact factor: 8.110
Authors: Roy Xiao; Yi An; Wenda Ye; Adeeb Derakhshan; Hui Cheng; Xinping Yang; Clint Allen; Zhong Chen; Nicole C Schmitt; Carter Van Waes Journal: Clin Cancer Res Date: 2019-07-02 Impact factor: 12.531
Authors: Roman C Brands; Mario J J Scheurer; Stefan Hartmann; Axel Seher; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2018-01-12 Impact factor: 2.967
Authors: Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg Journal: Apoptosis Date: 2017-07 Impact factor: 4.677